Physician profile
Ross A Summers
NPI 1689693590
$7,832.13
in general payments reported to CMS, 2019-2025
42 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,716 · 2020: $1,377 · 2021: $802 · 2022: $644 · 2023: $939 · 2024: $1,237 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.46 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $731.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $685.06 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $628.86 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $546.74 | 2019-2021 | |
| Pfizer INC. | $493.99 | 2019-2025 | |
| Astellas Pharma US INC | $414.57 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $333.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $327.80 | 2019-2022 | |
| Amgen INC. | $313.65 | 2019-2025 | Repatha, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $272.17 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $249.00 | 2019-2021 | |
| Allergan, INC. | $199.00 | 2019-2020 | |
| Exact Sciences Corporation | $197.56 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $191.04 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.